Magnetar Financial LLC Has $41.50 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Magnetar Financial LLC lowered its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 20.3% during the second quarter, Holdings Channel reports. The firm owned 3,712,258 shares of the biotechnology company’s stock after selling 947,120 shares during the period. Magnetar Financial LLC’s holdings in ADMA Biologics were worth $41,503,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ADMA. Quest Partners LLC bought a new position in ADMA Biologics during the second quarter valued at about $29,000. EntryPoint Capital LLC bought a new stake in ADMA Biologics during the first quarter worth approximately $31,000. CWM LLC lifted its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares during the last quarter. Acadian Asset Management LLC acquired a new position in ADMA Biologics during the 2nd quarter worth $93,000. Finally, Viewpoint Capital Management LLC boosted its stake in ADMA Biologics by 18.6% during the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Up 1.2 %

NASDAQ ADMA opened at $19.98 on Monday. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $20.16. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The stock’s 50 day moving average is $15.77 and its two-hundred day moving average is $11.00. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of -999.00 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same quarter last year, the company posted ($0.02) EPS. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. Equities analysts forecast that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ADMA shares. Mizuho upped their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. HC Wainwright upped their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ADMA Biologics currently has an average rating of “Buy” and a consensus price target of $15.50.

Insiders Place Their Bets

In other news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The disclosure for this sale can be found here. In the last quarter, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.